NovaBridge gains as eye disease drug shows promise in mid‑stage trial

NovaBridge Biosciences

09/03/2026 11:17

** Shares of drug developer NovaBridge NBP.O rise 6.6% to $3.73 premarket

** Co says its experimental drug, VIS-101, improved vision in people with wet age-related macular degeneration, a disease that damages the retina and causes vision loss in older adults

** Adds patients gained more than 10 letters on a standard eye chart and had reduced retinal swelling in a mid-stage study

** Says nearly half of the 38 patients in the trial needed no additional treatment for six months after three doses

** VIS‑101 well tolerated with no serious safety issues - co

** NBP plans larger dose-finding study in second-half of 2026 and global late-stage trial in 2027

** Shares rose nearly four-fold in 2025

 (Reporting by Sahil Pandey in Bengaluru)

 ((Sahil.Pandey@thomsonreuters.com))